PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33761747-6	2021	In the context of the BTK inhibitor ibrutinib, these electrophiles showed lower intrinsic thiol reactivity than the unsubstituted ibrutinib acrylamide.	Acrylamide	140-150	Bruton tyrosine kinase	Homo sapiens	22-25	
30442651-1	2019	Acalabrutinib is a targeted, covalent inhibitor of Bruton tyrosine kinase (BTK) with a unique 2-butynamide warhead that has relatively lower reactivity than other marketed acrylamide covalent inhibitors.	Acrylamide	172-182	Bruton tyrosine kinase	Homo sapiens	75-78	
27641927-9	2016	The drug binds tightly in the ATP-binding pocket of BTK making salt bridges with residues within the hinge that connects the two lobes of the enzyme; then its unsaturated acrylamide group forms a covalent bond with BTK cysteine 481 to form an inactive adduct.	Acrylamide	171-181	Bruton tyrosine kinase	Homo sapiens	52-55	
27641927-9	2016	The drug binds tightly in the ATP-binding pocket of BTK making salt bridges with residues within the hinge that connects the two lobes of the enzyme; then its unsaturated acrylamide group forms a covalent bond with BTK cysteine 481 to form an inactive adduct.	Acrylamide	171-181	Bruton tyrosine kinase	Homo sapiens	215-218	
32979005-2	2021	During the course of screening more potent and selective BTK inhibitors, we discovered that, MM2-48, an Ibrutinib analogue which contains the alkynyl amide functional group in place of the acrylamide warhead, exhibits a much stronger cytotoxicity.	Acrylamide	189-199	Bruton tyrosine kinase	Homo sapiens	57-60	
35247543-4	2022	Remibrutinib is a covalent inhibitor of Bruton"s Tyrosine kinase (BTKi) carrying a reactive acrylamide moiety (warhead), thus the potential contribution of covalent binding (off-target) to observed interactions was investigated as this could lead to prolonged and more potent drug interactions.	Acrylamide	92-102	Bruton tyrosine kinase	Homo sapiens	66-70	
34896750-3	2022	In this study, seven BTK-inhibitor drugs containing acrylamide warheads were incubated with human serum albumin (HSA) and analyzed using an LC-MS/MS peptide mapping approach to determine the amino acid sites of drug covalent binding.	Acrylamide	52-62	Bruton tyrosine kinase	Homo sapiens	21-24	
35587148-5	2022	Using the scaffold of the Bruton"s tyrosine kinase (BTK) inhibitor Ibrutinib for our proof-of-concept, we reasoned that increasing the steric bulk of fumarate-based electrophiles on Ibrutinib should improve selectivity via the steric exclusion of off-targets but retain rates of cysteine reactivity comparable to that of an acrylamide.	Acrylamide	324-334	Bruton tyrosine kinase	Homo sapiens	26-50	
35587148-5	2022	Using the scaffold of the Bruton"s tyrosine kinase (BTK) inhibitor Ibrutinib for our proof-of-concept, we reasoned that increasing the steric bulk of fumarate-based electrophiles on Ibrutinib should improve selectivity via the steric exclusion of off-targets but retain rates of cysteine reactivity comparable to that of an acrylamide.	Acrylamide	324-334	Bruton tyrosine kinase	Homo sapiens	52-55